Business Wire

Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation ...

Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma ...
Nature

Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy

Systemic targeted molecular therapy, in the form of a selective BRAF inhibitor with or without a MEK inhibitor, is a standard treatment for patients with BRAF V600 mutation-positive melanoma with ...
Science Daily

BRAF inhibitor treatment causes melanoma cells to shift how they produce energy

BRAF-positive metastatic malignant melanomas develop resistance to treatment with drugs targeting the BRAF/MEK growth pathway through a major change in metabolism, new research shows. The findings ...
ascopubs.org

Biomarker-driven access to vemurafenib in BRAF-positive cancers: Second study of the French National AcSé Program.

A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers. Phase I evaluation of the PI3 kinase (PI3K) inhibitor ...
Cure Today

Combination Approved for BRAF-Positive Lung Cancer

The combination of Tafinlar (dabrafenib) and Mekinist (trametinib) gained approval from the Food and Drug Administration (FDA) for the treatment of patients with BRAF V600–positive advanced or ...
FierceBiotech

Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive ...

Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma SOUTH SAN ...
FiercePharma

FDA approves Zelboraf (vemurafenib) and companion diagnostic for BRAF mutation-positive metastatic melanoma

First and Only Personalized Medicine Shown to Help People With BRAF V600E Mutation-Positive Metastatic Melanoma, Found in Half of Melanoma Patients, Live Longer Roche (SIX: RO, ROG; OTCQX: RHHBY) ...
Business Wire

Genentech Announces Phase III Study Results for Tecentriq Plus Cotellic and Zelboraf in People With Previously Untreated BRAF V600 Mutation-positive Advanced Melanoma

IMspire150 is a Phase III, multi-center, double-blind, placebo-controlled randomized study in people with previously untreated BRAF V600 mutation-positive metastatic or unresectable locally advanced ...
Nature

Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice

The detection of V600E BRAF mutation in melanoma is fundamental since here BRAF inhibitors represent an effective treatment. Non-V600E BRAF mutations that may also respond are not detected by certain ...
FiercePharma

FDA approves Zelboraf (vemurafenib) and companion diagnostic for BRAF mutation-positive metastatic melanoma, a deadly form of sk

First and Only Personalized Medicine Shown to Help People With BRAF V600E Mutation-Positive Metastatic Melanoma, Found in Half of Melanoma Patients, Live Longer Roche (SIX: RO, ROG; OTCQX: RHHBY) ...
FierceBiotech

FDA Approves Zelboraf (Vemurafenib) and Companion Diagnostic for BRAF Mutation-Positive Metastatic Melanoma, a Deadly Form

-- First and Only Personalized Medicine Shown to Help People With BRAF V600E Mutation-Positive Metastatic Melanoma, Found in Half of Melanoma Patients, Live Longer -- SOUTH SAN FRANCISCO, ...